Marshall Keith W 4
4 · Prometheus Biosciences, Inc. · Filed Jun 2, 2023
Insider Transaction Report
Form 4
Marshall Keith W
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2023-06-02$3.10/sh+78,162$242,302→ 87,973 total - Exercise/Conversion
Stock Options (Right to Buy)
2023-06-02−78,162→ 52,838 totalExercise: $3.10Exp: 2030-08-11→ Common Stock (78,162 underlying)
Footnotes (2)
- [F1]This transaction represents an exercise and hold of stock options by the Reporting Person for tax planning purposes.
- [F2]25% of the shares subject to the option vested and became exercisable on August 3, 2021, and 1/48th of the shares subject to the option vesting monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date.